card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines

Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines
Home / Insights / Dexrazoxane enhances efficacy of all-trans retinoic acid in acute myeloid leukemia patient blast cells and cell lines

All trans retinoic acid (ATRA) has demonstrated curative activity in acute promyelocytic leukemia (APL), a distinct subtype of acute myeloid leukemia (AML), that is characterized by a chromosomal translocation t(15;17) involving the retinoic acid receptor alpha (RARα) and promyelocytic leukemia (PML) genes. When ATRA is used in combination with arsenic trioxide, most APL patients achieve complete remission. However, success with this relatively nontoxic strategy has not fully translated to other AML subtypes. Early clinical trials of ATRA with anthracycline-based chemotherapy or arsenic trioxide provided conflicting results with potential benefits being restricted to distinct AML subtypes. ATRA in combination with arsenic trioxide has been shown to induce apoptosis in NPM1-mutated AML cell. A 21 gene-expression model (ATRA-21) has been developed to predict AML sub-type specific sensitivity to ATRA. Recently it was shown that addition of ATRA to decitabine resulted in higher remission rates in elderly AML patients. These findings suggest that ATRA-based combination therapies have the potential of being clinically effective in non-APL AML and merit investigation of novel, less toxic combination strategies with ATRA, especially for treating older patients who may be ineligible for toxic induction chemotherapy. Previously we reported that the anti-proliferative effects of ATRA in AML and APL cell lines were potentiated when topoisomerase (topo) IIβ was depleted or when topo IIα/topo IIβ were catalytically inhibited by the bis (2,6 dioxypiperazine) derivative, ICRF-193. Since the clinically approved topo II catalytic inhibitor, dexrazoxane (Dex), is frequently used as an effective cardioprotectant in pediatric AML patients treated with anthracycline-based therapy and shown to lower treatment related mortality, in this study we examined the effectiveness and mechanisms of the combination of ATRA with Dex, in AML patient blast cells and established AML cell lines.

Read full article here.